Welcome to our dedicated page for Cellectar Biosciences SEC filings (Ticker: CLRB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellectar Biosciences Inc (CLRB) maintains SEC reporting requirements as a NASDAQ-listed clinical-stage biopharmaceutical company. The company's filings document its financial position, clinical development activities, and corporate governance—information particularly relevant for investors evaluating early-stage biotechnology firms without product revenue.
Form 10-Q quarterly reports detail Cellectar's cash position, operating expenses, and clinical trial expenditures. For clinical-stage companies, the cash runway calculation—current cash divided by quarterly burn rate—indicates how long the company can fund operations before requiring additional financing. Research and development expenses in 10-Q filings reflect the cost of advancing therapeutic candidates through clinical trials, while general and administrative expenses show overhead costs. Our AI summaries highlight these key metrics, saving you from parsing complex accounting disclosures.
Form 10-K annual reports provide comprehensive overviews of Cellectar's business, including detailed pipeline descriptions, clinical trial designs, intellectual property portfolios, and risk factors specific to radiopharmaceutical development. These documents explain the PDC platform technology, orphan drug designations, and regulatory strategies in management's own language. The risk factors section identifies challenges including clinical trial uncertainties, financing needs, radioisotope supply dependencies, and competitive dynamics.
Form 8-K current reports disclose material events as they occur: financing transactions, clinical trial results, regulatory decisions, partnership agreements, and corporate changes. For Cellectar, 8-K filings often announce public offerings, supply agreements for radioisotopes, FDA designations, and other time-sensitive developments. These real-time disclosures provide immediate notification of significant corporate events.
Form 4 insider trading reports track stock transactions by company executives and directors. In clinical-stage biotechnology, insider buying may signal management confidence, while selling could reflect personal liquidity needs or portfolio diversification. Our platform aggregates Form 4 filings, making it easy to monitor executive transaction patterns without manually reviewing individual reports.
Prospectus filings including Form S-1 registration statements and 424B documents detail public offerings, including share counts, pricing, and use of proceeds. These filings explain how Cellectar intends to deploy capital raised through equity offerings, typically focusing on clinical trial funding and general corporate purposes. Understanding offering terms and dilution impact helps investors assess the effect of new financings on existing shareholdings.
Cellectar Biosciences reports a mixed quarter: clinical progress on its lead radioconjugate and significant financial strain. Total assets declined to $13.7 million from $25.5 million, driven by a fall in cash and cash equivalents to $11.04 million from $23.29 million. The company recorded a net loss of $12.05 million for the six months and has an accumulated deficit of approximately $259.4 million. Operating expenses for the six months totaled $12.44 million, composed of research and development of $5.82 million and general and administrative of $6.62 million.
Operationally, Cellectar received Breakthrough Therapy Designation for iopofosine I-131 in relapsed/refractory Waldenstrom macroglobulinemia and reported strong CLOVER WaM results: a major response rate of 58.2% and an overall response rate of 83.6%. Development programs CLR 125 and CLR 225 are positioned for Phase 1 trials in 2025 but are explicitly conditioned on obtaining additional financing. Management discloses substantial doubt about going concern, with available liquidity near $15 million and runway described as limited absent further financing; planned actions include sales of equity/debt, strategic transactions, and cost savings. A July 2, 2025 underwritten offering raised approximately $6.9 million gross as a subsequent event.
Cellectar Biosciences, Inc. is reported to have Hexstone Capital LLC and Brendan O'Neil as joint reporting persons that beneficially own 150,000 shares of common stock, representing 5.6% of the outstanding shares used for this calculation. The percentage is calculated on a post-offering share count of 2,677,039 shares disclosed in the issuer's prospectus. Hexstone also holds 150,000 warrants exercisable for common stock, but those warrants are not included in the ownership total because they are subject to a 4.99% ownership limitation that blocks exercise if it would increase beneficial ownership above that threshold. Mr. O'Neil is the managing member of Hexstone and may be deemed to beneficially own the shares held by Hexstone; he does not directly own the shares. The filing includes a certification that the securities were not acquired to change or influence control of the issuer.
FAQ
What is the current stock price of Cellectar Biosciences (CLRB)?
What is the market cap of Cellectar Biosciences (CLRB)?
